Dr. Philip Castle is a Professor in the Department of Epidemiology and Population Health at Albert Einstein College of Medicine, Bronx, N.Y., USA. He is a Visiting Professor at the National University Health System of Singapore. Previously, he was a Visiting Professor at the Cancer Institute/Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College in Beijing, P.R. China and an Honorary Professor at the University of New South Wales, Sydney, Australia. Dr. Castle was the Chief Scientific Officer of the American Society for Clinical Pathology (ASCP) (2011-2). He was a Senior, Tenured Investigator (2010-11) and Tenure-Track Investigator (2003-10) in the Division of Cancer Epidemiology and Genetics (DCEG) at the U.S. National Cancer Institute (NCI). He received his Ph.D. in Biophysics in 1995 and M.P.H. in Epidemiology in 2000 from the Johns Hopkins University.
Dr. Castle’s professional interests are (1) epidemiology of human papillomaviruses (HPV) and cervical/anogenital cancer; (2) science and translation of cancer prevention strategies; (3) cancer screening; (4) international health; (5) health services research; and (6) evidence-based medicine. While at the NCI, he was the lead investigator on several epidemiologic studies, including the Mississippi Delta Project, The HPV Persistence and Progression Cohort and The Guidelines Cohort at Kaiser Permanente Northern California (KPNC), and the Anal Cancer Screening Study. He remains co-PI of The Guidelines Cohort at KPNC. Dr. Castle is currently conducting cancer screening and treatment research and work in Australia, Papua New Guinea, Norway, El Salvador, Brazil, Peru, Colombia, Mexico, India, Cameroon, Nigeria, Rwanda, and Mozambique as well as in the U.S.
Dr. Castle has published almost 400 papers on HPV and cervical and anogenital cancers and has contributed articles to such prestigious journals as the New England Journal of Medicine, Lancet, Lancet Oncology, Journal of the National Cancer Institute, British Medical Journal, JAMA, Archives for Internal Medicine, and Cancer Research. He previously served on the editorial boards of the Journal of Infectious Diseases, Journal of Lower Genital Tract Disease and currently serves on the editorial boards of Cancer Prevention Research and Papillomavirus Research. Dr. Castle has served as an invited speaker or session chair in many forums, including for the American Association for Cancer Research, International Papillomavirus Society, and the European Union on Genital Infection and Neoplasia.
Dr. Castle regularly participates in the development of national and international guidelines for cervical cancer prevention. He was a member on the Centers for Disease Control and Prevention’s (CDC) National Breast and Cervical Cancer Early Detection and Prevention (NBCCEDP) Advisory Committee, the Board of Directors of the American Society for Colposcopy and Cervical Pathology (ASCCP), and the steering committee for American Society for Clinical Oncology’s Cervical Cancer Resource Stratified Secondary Prevention Guideline Panel. He was a recent member of WHO Strategic Advisory Committee on in Vitro Diagnostics (SAGE IVD) (http://www.who.int/medical_devices/diagnostics/SAGE_IVD_2018_member_list/en/).
Dr. Castle currently is the Associate Chair of Cancer Prevention and Control and serves on the HPV and Solid Tumor Working Groups for the AIDS Malignancy Consortium. He is a member of/participant in the WHO Guidelines Groups for Thermoablation for Cervical Treatment and Cervical Screening and Treatment , Expert Advisor of American Cancer Society (ACS) Guideline Development Group (GDG) for Cervical Cancer Screening, Consultant to Health Directorate of Norway and Member of the Academic (Faglig) Panel of the Cancer Registry of Norway for an implementation study of primary HPV testing of cervical cancer screening in Norway, Member of HPV Test Characteristics Expert Panel for Cancer Care Ontario, and member of the Risk Based Management Guidelines and Co-Chair of the Surveillance Group for the ASCCP.
For his work in cervical cancer prevention, Dr. Castle has received (1) An EUROGIN Distinguished Service Award (2006); (2) a NIH Merit Award for introduction of HPV testing into low-resource settings in the U.S. (2007); (3) a Distinguished Scientific Achievement Award from the ASCCP (2010), its highest honor; (4) The Arthur S. Flemming Award for Exceptional Achievement in Federal Government Service for Applied Science, Engineering and Mathematics (2010); and (5) NCI Cancer Prevention Fellowship Program Distinguished Alumni (2017-8).